Skip to content

To compare two methods of treatment for persistent cervical discharge in patients

Comparison of thermoablation with cryotherapy for the treatment of symptomatic cervical ectropion:A Randomized Controlled Trial - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/10/059097
Enrollment
64
Registered
2023-10-25
Start date
Unknown
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: N86- Erosion and ectropion of cervix uteri

Interventions

Intervention1: Thermoablation: Thermoablation is an alternative method to cryotherapy. Similar effectiveness between thermoablation and cryotherapy has been found in published studies [9] . The primar

Sponsors

none
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Women >21 years of age with symptomatic cervical ectropion including persistent discharge ,post coital bleeding and intermenstrual bleeding. Persistence of atleast 1 symptom for 3 months or recurrence of symptoms twice in 3 months despite obtaining medical treatment. Normal PAP smear. Visible cervical ectropion >0.5 cm from the external os. Willingness of the patient to participate in the study. Women understanding spoken or written hindi.

Exclusion criteria

Exclusion criteria: Women with diagnosed Carcinoma Cervix or pre-invasive lesion of cervix in the past. Previous cervical ablation procedures and loop electrosurgical excision procedure (LEEP). Pregnant women. Women with active vaginal infection. Women currently using oral contraceptive pills.

Design outcomes

Primary

MeasureTime frame
Change in the size of the cervical ectropion 6 & 12 weeks after colposcopic guided thermoablation.Timepoint: Baseline 6 weeks 12 weeks

Secondary

MeasureTime frame
Percentage of women experiencing side effects at 6 weeks & 12 weeks post procedure Timepoint: Baseline 6 weeks 12 weeks;Change in the severity of symptoms assessed with the VAS analogue scale. Timepoint: Baseline 6 weeks 12 weeks;Change in the WHOQOL-BREF questionnaire score. Timepoint: Baseline 6 weeks 12 weeks

Countries

India

Contacts

Public ContactHARBANI SONI

Lady Hardinge Medical College

drswatilhmc@gmail.com9810181964

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026